OcuCure Therapeutics, Inc. is an ophthalmic pharmaceutical company developing new proprietary drugs. The company’s lead compound has been formulated as a topical eye drop for both Age-related Macular Degeneration (AMD) and Diabetic Retinopathy (DR). AMD and DR are leadingcauses of blindness in developed countries. 

Additionally, the lead compound has potential for use as a prophylactic. The presence of the therapeutic target has been validated in human AMD and DR tissues. This confirms the OcuCure approach for treating ocular angiogensis. The topical eye drop also has demonstrated the ability to cross human corneas in in vitro studies. When the eye drop was administered to animals, the lead compound penetrated all the way back to the retina at clinically significant concentrations without any toxic effects observed. By comparison, the currently available drugs for AMD are administered by a monthly injection into the eye.